469 results about "Intestinal microorganisms" patented technology

A database structure obtained by means of information retrieval, and a reasoning system, which structure and system specifically relate to a gut microbe knowledge graph system, comprising: a gut microbe knowledge graph consisting of a gut microbe knowledge base, a gut microbe and small-molecule drug therapy association knowledge base, and a clinical medicine database; and a multimodal uncertainty reasoning system, using the gut microbe knowledge graph. The gut microbe knowledge graph system predicts potential diseases, drugs, genes, etc., which are associated with gut microbes.

The invention discloses intestinal bacteria and serum metabolites which can be used as biomarkers of type 2 diabetes mellitus (prediabetes mellitus (PDM), new diagnosis diabetes mellitus (NDDM) and diabetes mellitus (P2DM) after medication) in different disease stages, and application of the intestinal bacteria and the serum metabolites. Aiming at type 2 diabetes mellitus, predictive markers including staphylococcus aureus, escherichia coli, klebsiella pneumoniae, branched chain amino acids (leucine, valine and isoleucine) and the like, especially staphylococcus aureus of which the genome contains acetolactate synthase (ALS), are efficiently screened out. The type 2 diabetes mellitus marker disclosed by the invention can be used for early warning the illness risk of type 2 diabetes mellitus and guiding the adjustment of an intestinal microbial environment; the method can be used for indicating the correlation between the intestinal microbial environment and the type 2 diabetes mellitus and is used for assisting diagnosis; and drug action target research, accurate medication, pathogenesis research and the like are realized.

The invention provides a myocardial amyloidosis classification prediction method and system based on cardiac magnetic resonance multi-sequence radiomics, and is applied to the technical field of data processing. The method comprises the following steps: preprocessing cardiac magnetic resonance multi-sequence image information to generate a standardized multi-sequence image data set; processing the standardized multi-sequence image data set to generate a target image omics feature vector; processing the gene detection information to generate pathogenic gene characteristics and mutation type characteristics; processing the target radiomics feature vectors and the cardiac magnetic resonance parameters based on medical knowledge graph data to generate an AL type myocardial feature associated feature set and an ATTR type myocardial feature associated feature set; processing the blood detection index information and the intestinal microflora parameter information to generate myocardial amyloidosis influence factors; and processing the data based on the target myocardial amyloidosis classification prediction model to generate a myocardial amyloidosis classification prediction result.

The invention discloses a triggering probiotic-drug conjugate and a preparation method and application thereof, and belongs to the technical field of oral drug delivery systems, the triggering probiotic-drug conjugate comprises probiotics, an adhesive inner layer formed by coordination of tannic acid and Fe < 3 + >, and an outer layer formed by pterostilbene-phospholipid bridged by ROS-responsive thioether bonds and cholesterol; the inner layer coats the surfaces of the probiotics through coordination, and the outer layer coats the outer part of the inner layer through self-assembly. An outer lipid layer is decomposed under high-concentration ROS in an inflammation colon area, and probiotics coated with pterostilbene and a tannic acid layer are released. Pterostilbene relieves inflammation and rebuilds a pathological microenvironment, and catechol groups in a tannic acid layer and the surface of the intestinal tract generate multiple interactions to promote planting of probiotics. In UC mouse models, the conjugates exhibit enhanced therapeutic effects by inhibiting inflammation, restoring intestinal barrier function, and improving intestinal microbiota homeostasis. The invention has important transformation potential in clinical application of gastrointestinal diseases.

The invention discloses a brain glioma intestinal microbial marker, a product and application of the brain glioma intestinal microbial marker, and belongs to the field of biological medicine. The invention relates to an enteric microbial marker, which is characterized by being prepared from one or more of Eubacter algenti, Prevotella copri, Alistipes finegili, Bifidobacterium adolescentis and Citrobacter sp., and the enteric microbial marker is prepared from one or more of Eubacter algenti, Prevotella copri, Alistipes finegili, Bifidobacterium adolescentis and Citrobacter sp., and the enteric microbial marker is prepared from one or more of Eubacter algenti, Prevotella copri, Alistipes finegili, Bifidobacterium adolescentis and Citrobacter sp. The invention provides a kit which comprises a detection reagent for detecting the relative abundance of the intestinal microbial marker. The invention provides a product for diagnosing brain glioma and a computer program product related to the brain glioma. The product provided by the invention has good feasibility and accuracy, and provides a new tool for clinical diagnosis.

Provided are a mixture of three species of Lactobacillus fermentum strain and Lactobacillus plantarum strain and use thereof. A composition according to one aspect including, as an active ingredient, a mixture of Lactobacillus fermentum strains GB102 and GB103 and Lactobacillus plantarum strain GB104; or a lysate or culture solution thereof, or an extract of the culture solution, can be usefully used for the prevention or treatment of muscle-related disorders or obesity by alleviating the decrease in grip strength induced by aging or reducing the change in intestinal microbial environment induced by aging.

The invention belongs to the technical field of microorganisms, and particularly relates to lactobacillus plantarum GL-2 and application thereof. The invention provides a strain of lactobacillus plantarum which is preserved in the 8th road of Wuchang District in Wuhan City, Hubei Province on March 15, 2023, and the preservation number is CCTCC M 2023328. The results of the embodiment show that the lactobacillus plantarum GL-2 provided by the invention has the effects of reducing blood sugar and blood fat, and the lactobacillus plantarum GL-2 provided by the invention also has the effects of repairing inflammation damaged organs and regulating intestinal microorganisms.

A nutritional composition comprising sn-2 palmitic acid and A2 beta-casein for use in improving the gut microbiota in a human subject.

The invention discloses application of animal bifidobacterium subsp. Lactis GOLDGUT-BB21 in preparation of products for relieving depression, and belongs to the technical field of biological medicine. The probiotics disclosed by the invention can be used for relieving depressive symptoms, improving related symptoms, assisting in treating depression and preventing depression, and also can be used as a nutritional supplement to help maintain the balance of intestinal microflora and promote intestinal health.

The invention belongs to the field of biological medicines, and particularly relates to application of loganic acid in preparation of a medicine for treating arthritis. Specifically, through experimental research of a collagen-induced arthritis mouse model, the loganin acid is found to be capable of remarkably relieving arthritis symptoms, relieving joint swelling, synovitis and cartilage injury in a dose-dependent manner, and reducing the levels of proinflammatory factors TNF-alpha and IL-6 in plasma. By further combining 16S rRNA sequencing analysis, the loganic acid can remarkably regulate the intestinal microbiota structure of arthritis mice, increase the abundance of Lactobacillus murinus in the intestinal tract and promote the generation of tryptophan metabolite indole-3-acetic acid, so that the effect of resisting rheumatoid arthritis is achieved through an intestinal flora dependent mechanism. Therefore, the invention provides a new application of loganin acid in preparation of a medicine for treating arthritis, and the compound has further research and application values as a potential small molecule medicine.

The invention discloses a feed containing astragalus polysaccharide and a preparation method thereof, and belongs to the field of feeds. The astragalus polysaccharide is added into the basic feed, so that the adverse effect of heat stress on the female rabbits can be effectively relieved, the conception rate of the female rabbits, the number of live litters and the average weight of the live litters can be increased, and the breeding economic benefits are improved while the reproductive performance is optimized and the growth of the young rabbits is promoted; the prepared feed can effectively improve the serum hormone level of animals and reduce the inflammatory factor level, meanwhile, the diversity of animal intestinal microorganisms under heat stress is effectively improved, a scientific basis is provided for precise feeding management of domestic rabbits in summer, and meanwhile, an important reference is provided for application of astragalus polysaccharide in the field of livestock and poultry anti-stress.

The invention discloses an intestinal microbial marker related to non-alcoholic fatty liver, a product and application of the intestinal microbial marker, and belongs to the field of biological medicine. The microbial marker is prepared from one or more of streptococcus anginiae, bacteroides faecalis, bifidobacterium adolescentis and hispidaceae bacteria. The invention provides a kit which comprises a detection reagent for detecting the relative abundance of the microbial marker. The invention further provides a product for diagnosing the non-alcoholic fatty liver disease, a prediction system for evaluating the risk that a to-be-detected object is a patient with the non-alcoholic fatty liver disease, and a computer program product related to the non-alcoholic fatty liver disease. The product provided by the invention has good feasibility and accuracy, can effectively evaluate the risk of the non-alcoholic fatty liver disease, and provides a new tool for clinical diagnosis.

Provided is a Bifidobacterium lactis. The Bifidobacterium lactis is Bifidobacterium animalis subsp. lactis BL-11, and the preservation number of the Bifidobacterium animalis subsp. lactis BL-11 is CGMCC No. 20847. The provided Bifidobacterium animalis subsp. Lactis can improve intestine metabolism disorder and normalize the composition of intestine microbiome so as to improve height, suppresses obesity, promote infant and youth physical development and mental development, and prevent and treat mental disorders, said mental disorders including anxiety, depression, attention-deficit / hyperactivity disorder, autism, schizophrenia, hepatic encephalopathy, anorexia, Tourette syndrome, and Asperger syndrome.

The invention discloses preparation and application of aquatic plant extracellular vesicles with an intestinal barrier regulating function, and belongs to the field of bioengineering technology and health food. The method mainly comprises the following steps: efficiently extracting aquatic plant extracellular vesicles by utilizing a tangential phase flow technology, and researching the functional activity of the aquatic plant extracellular vesicles. The obtained extracellular vesicles have good intestinal stability and biocompatibility, and also have significant antioxidant activity and anti-inflammatory effect. In a carbon tetrachloride induced chronic hepatic fibrosis model, the extracellular vesicles can reduce LPS (Lipopolysaccharide) generated by excessive reproduction of intestinal microorganisms from entering the liver by regulating intestinal tight junction protein, so that the liver inflammation is relieved. In addition, the extracellular vesicles can also regulate intestinal flora and immune barriers, and inflammatory response caused by chronic hepatic fibrosis is relieved through the intestinal liver axis. The extracellular vesicles prepared by the method have wide application prospects and economic benefits in anti-inflammatory drugs, nano-drug carriers and functional skin care products.

The invention discloses a meningioma enteric microbial marker, a product and application of the meningioma enteric microbial marker, and belongs to the field of biological medicine. The invention relates to an enteric microbial marker, which is characterized by being prepared from one or more of the following components: parabacteroides dissoni, prevotella copri, bifidobacterium adolescentis and streptococcus salivarius, and is characterized in that the enteric microbial marker comprises one or more of the following components: parabacteroides dissoni, prevotella copri, bifidobacterium adolescentis and streptococcus salivarius, and the enteric microbial marker comprises one or more of parabacteroides dissoni, prevotella copri, bifidobacterium adolescentis and streptococcus salivarius. The invention provides a kit which comprises a detection reagent for detecting the relative abundance of the intestinal microbial marker. The invention provides a product for diagnosing meningioma and a computer program product related to meningioma. The product provided by the invention has good feasibility and accuracy, can effectively evaluate the risk of meningioma, and provides a new tool for clinical diagnosis.

A method for improving gut microbiota population in a subject by administering a composition comprising allulose, erythritol or a combination thereof. A method for increasing one or more colonic bacterial populations from the families Lachnospiraceae or Eubacteriaceae by administering a composition comprising allulose, erythritol or a combination thereof. A method for preventing, treating or ameliorating a disease in a subject by administering a composition comprising allulose, erythritol or a combination thereof. The disease may be one or more of metabolic syndrome, obesity, type 2 diabetes, insulin resistance, hyperlipoproteinemia, hyperuricemia, hepatic steatosis, hypercholesterolemia, hypertriglyceridemia, irritable bowel syndrome (IBS), colon cancer, allergy, non-alcoholic fatty liver disease, inflammatory bowel disease, cardiovascular disease, or inflammation. The bacterial population may be the species Anaerostipes hadrus, Blautia obeum, Anaerobutyricum hallii, Eubacterium rectale (Agathobacter rectalis), Eubacterium callanderi, Eubacterium limosum and Eubacterium maltosivorans. A composition comprising allulose, erythritol or a combination thereof and one or more colonic bacterial populations from the families Lachnospiraceae or Eubacteriaceae is also provided. The composition may in the form of a food composition.

The invention belongs to the technical field of food engineering, and particularly relates to an anti-allergic special medical infant milk protein partial hydrolysis formula food composition, a preparation method and application. According to the infant milk protein partial hydrolysis formula food composition for the special medical purpose, the mass ratio of the 2 '-fucosyllactose to the lactobacillus acidophilus NCFM to the bifidobacterium animalis Bi-07 is (150-200): (5-10): (2-8). The partially hydrolyzed formula food composition provided by the invention can prevent respiratory tract infection and maintain the natural defense capability of children; the infant health is promoted; the method helps infants to establish healthy intestinal microflora, which is crucial to immune system and cognitive development.

Provided herein are compositions, methods, strategies, kits, and articles of manufacture that are useful, inter alia, in the treatment or prevention of diseases or conditions such as those which may be associated with inflammation, infection, allergy, immune dysfunction, or dysbiosis of the intestinal microbiome. In some aspects, the invention provides a synergistic combination of a prebiotics, e.g., a mixture of human milk oligosaccharides, and a probiotic strain, such as a strain capable of internalizing and consuming the rebiotics, e.g., B. longum subsp. infantis.

Various benefits to intestinal health are made by delivery of an active agent to the colon of an animal, including a human. Active ingredients include of riboflavin, vitamin A, vitamin C, vitamin D, vitamin E, vitamin K, folic acid, β-carotene, vitamin B1, niacin, vitamin B5, vitamin B6, biotin, vitamin B12, omega-3 fatty acids and combinations thereof. Benefits include increased concentration of at least one short-chain fatty acid its salt thereof in the intestine, increased microbiome diversity in the intestine, increased beneficial bacteria in the intestine, increased the butyrate synthesis pathway in the intestine, improved barrier function of the intestine, reduced redox potential of the gut, reduced amount of gas produced in the intestine; and stimulation of intestinal immune responses.

The present invention belongs to the field of microorganisms, and more specifically, the present invention relates to Lactobacillus sanfranciscous ( Lactobacillus_ sanfranciscensis The present invention relates to the use of a microbial agent in the prevention, diagnosis and / or treatment of attention deficit hyperactivity disorder (ADHD), and a microbial preparation for the prevention and / or treatment of ADHD. This provides further evidence for the correlation between the gut microbiota and ADHD, and also provides new candidates for the treatment of ADHD.

The invention provides a composition for promoting differentiation of intestinal immune cells as well as a preparation method and application of the composition. According to the composition, 1, 3-dioleic acid-2-palmitic acid triglyceride and breast milk oligosaccharide are used in a combined manner, so that monocytes can be effectively promoted to differentiate into intestinal macrophages, and inflammation is reduced to a certain extent. After the monocytes are differentiated into the intestinal macrophages, the intestinal immune homeostasis and intestinal microbiota inflammatory response can be regulated, so that the mucosal immune homeostasis and intestinal epithelial cell barrier function are maintained. Therefore, the composition provided by the invention can improve the intestinal immune barrier by promoting the monocytes to differentiate into the intestinal macrophages, and provides a new thought for improving the early intestinal barrier of infants through nutritional supplement.

The invention belongs to the technical field of biological medicine, and relates to application of a clerodendranthus spicatus tea bag in regulating intestinal excretion and reducing uric acid. One of the purposes of the invention is to provide the application of the clerodendranthus spicatus teabag in regulating intestinal tracts to reduce uric acid According to a preferred embodiment, the clerodendranthus spicatus teabag regulates ATP binding cassette transporter G2 and inhibits uricase activity. The invention provides the application of the clerodendranthus spicatus teabag in regulating the intestinal microbial environment and reducing uric acid, and the clerodendranthus spicatus teabag has remarkable beneficial effects. The clerodendranthus spicatus teabag can effectively regulate the structure and the function of intestinal microflora, especially the enrichment amount of characteristic bacteria Muriaculum in the intestinal tract, further strengthens the probiotic activity of the intestinal flora, and is helpful for maintaining the steady state of uric acid in the body. The multi-way synergistic effect not only provides an innovative strategy for preventing and treating hyperuricemia and related metabolic diseases, but also avoids side effects possibly brought by traditional medicines, and shows good application prospects and clinical values.

The invention belongs to the technical field of medical diagnosis, and provides an HIV (human immunodeficiency virus) combined non-alcoholic fatty liver diagnosis and prediction marker and application. The marker comprises 39 biomarkers in total, wherein the 39 biomarkers comprise two intestinal microorganisms of enterobacter and klebsiella and 37 plasma metabolites of diacylglycerol, lysophosphatidic acid and the like; by integrating microbiome and metabonomics, the multi-dimensional marker is screened and verified, so that the problems of lack of high specificity and sensitivity, difficulty in early disease screening and incapability of effective risk assessment of an HIV (Human Immunodeficiency Virus) combined NAFLD (Non-Amplified Fragment Leukemia) early diagnosis method caused by unknown pathogenesis in the prior art are solved; the marker combination is applicable to preparation of diagnostic kits, construction of disease prediction models and development of targeted therapy drugs, and a theoretical basis is provided for early discovery, risk early warning and advanced intervention of the HIV combined with the non-alcoholic fatty liver disease.

The invention relates to the technical field of bioinformatics and medical artificial intelligence data processing, in particular to a colorectal cancer risk assessment system based on intestinal microbiological diversity, which comprises a multi-modal time sequence data acquisition module, a multi-modal time sequence data acquisition module, a target object microbiome time sequence feature data acquisition module and a target object microbiome time sequence feature data acquisition module, obtaining current medical resource load state parameters; the compliance entropy calculation module is used for resolving longitudinal compliance entropy representing the data uploading continuity willingness of the target object; the artifact interference identification module is used for generating a physiological disturbance probability value and a denoised pathological evolution feature vector; the double-constraint risk assessment module is used for calculating an initial pathological risk index of the target object; the dynamic decision scheduling module is used for determining a final dynamic intervention strategy for the target object; according to the method, the false positive and false alarm rate is remarkably reduced, and the technical pain point that real pathological evolution and environmental interference are difficult to distinguish by a traditional method is solved.

The present invention relates to a composition for alleviating obesity, improving cognitive function and memory, and preventing Alzheimer's disease, comprising a fermented hemp seed product as an active ingredient. The fermented hemp seed product prepared by inoculating a Pediococcus acidilactici OHSI1 strain (deposit number: KCTC 15831BP) strain, of the present invention, has the effects of: increasing the abundance and diversity of intestinal microorganisms; increasing beneficial intestinal bacteria; reducing harmful intestinal bacteria; alleviating intestinal microbial flora imbalance; anti-obesity; antioxidation; and controlling Alzheimer's disease-associated enzyme activity, and thus can be effectively used as a food composition or a pharmaceutical composition for preventing, alleviating, or treating obesity or cognitive dysfunction, and as a health functional food composition for improving memory and cognitive function by improving intestinal microbial flora.

The present disclosure relates to microbiome compositions for improving muscle strength using a heat-treated fermentative culture complex of KM2 Phytobacterium plantarum. The composition according to the present disclosure increases the synthesis of myoprotein and exhibits an effect of inhibiting the degradation of myoprotein. Animal tests show effects of improving muscle strength and increasing leg muscle mass by increasing grip strength, travel distance and speed, and results of improving popliteal muscle strength and increasing muscle mass even in clinical tests. Furthermore, it has been found that beneficial bacteria are increased by an increase in the diversity of the gut microbial flora, which varies as muscle decreases, and an improvement in the microbial flora composition, while harmful bacteria are reduced. Therefore, the composition can be used as a composition for preventing, alleviating or treating muscle diseases and a composition for improving muscle strength or increasing muscle mass.

The invention belongs to the technical field of biology, and particularly relates to lactobacillus paracasei and application thereof in improvement of gastric ulcer. The lactobacillus paracasei NCU-21 is preserved in China General Microbiological Culture Collection Center (CGMCC) on September 25, 2023, the address of the lactobacillus paracasei NCU-21 is No.3, No.1 yard, Beichen West Road, Chaoyang District, Beijing, and the preservation number of the lactobacillus paracasei NCU-21 is CGMCC NO.28538. The lactobacillus paracasei NCU-21 is named as Lactobacillus paracasei NCU-21. The invention provides a strain of lactobacillus paracasei NCU-21, and the data result of the embodiment shows that the lactobacillus paracasei NCU-21 can promote the healing of ethanol gastric ulcer and improve gastric mucosal lesion caused by oxidative stress. In addition, the strain can also regulate stomach microbiota, improve ethanol-induced gastric mucosal lesion, improve ethanol-induced intestinal inflammation, repair intestinal barriers and relieve ethanol-induced intestinal microbiota disorder.

The invention discloses an artificial intelligence-based intestinal microorganism regulating device, which comprises a wearable shell, an output motor is arranged in the wearable shell, the output motor is fixedly connected with a third bevel gear, the third bevel gear is in meshed connection with a fourth bevel gear, and a collecting mechanism is arranged on one side of the fourth bevel gear. The collecting mechanism comprises a disc bin arranged on the side portion of a fourth bevel gear, a second collecting opening is formed in the surface of the disc bin, and aiming at the problems that the reaction of the intestinal tract to traditional conditioning means such as massage is different, and especially the symptom of a diarrhea patient is prone to being aggravated due to improper massage, the device abandons a universal intervention mode lacking pertinence. Basic information such as gastrointestinal motility rhythm, pH value and temperature is carefully captured through the gastrointestinal data processor, and in combination with subsequent accurate detection and image shooting of microbial flora in the intestinal tract, diarrhea patient groups with sensitive intestinal tracts and susceptible to external stimulation are effectively discriminated.

The invention discloses application of a combination of probiotics GOLDGUT-M520 and GOLDGUT-LR99 in preparation of a product for relieving depression, and belongs to the technical field of biological medicines. The probiotics disclosed by the invention can be used for relieving depressive symptoms, improving related symptoms, assisting in treating depression and preventing depression, and also can be used as a nutritional supplement to help maintain the balance of intestinal microflora and promote intestinal health.

The invention provides application of bacillus tequilensis Bt-CO as a feed additive in largemouth bass culture, and belongs to the technical field of largemouth bass culture. The preservation number of the bacillus tequilensis Bt-CO is GDMCC No: 64960, the influence of the Bt-CO on the growth, survival, physical signs, immunity, antioxidant reaction, digestive enzyme, disease resistance, intestinal microbiota and metabolism of the largemouth bass is evaluated, and the probiotic potential of the Bt-CO and the effect of the Bt-CO in enhancing the resistance of the largemouth bass to aeromonas veronii infection are proved; bt-CO can be developed into a substitute of antibiotics, and a theoretical framework and a practical basis are provided for reasonable application of probiotics in aquaculture.